Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment

BACKGROUND: Interleukin (IL) 1 released from monocytes/macrophages is one of the critical determinants in mediating the adverse events of chimeric antigen receptor T cell (CAR-T) therapy, including cytokine release syndrome and neurotoxicity. However, the molecular mechanisms of IL-1 production duri...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dan, Xu, Xiyue, Dai, Yulian, Zhao, Xuan, Bao, Shunshun, Ma, Wen, Zha, Li, Liu, Shuci, Liu, Yuchen, Zheng, Junnian, Shi, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797290/
https://www.ncbi.nlm.nih.gov/pubmed/33414262
http://dx.doi.org/10.1136/jitc-2020-001466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797290/
https://www.ncbi.nlm.nih.gov/pubmed/33414262
http://dx.doi.org/10.1136/jitc-2020-001466

Ejemplares similares